Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Favipiravir (T-705) 是一种有效且选择性的 RNA 依赖性 RNA 聚合酶抑制剂,用于治疗流感病毒感染。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 659 | 现货 | ||
10 mg | ¥ 1,177 | 现货 | ||
50 mg | ¥ 2,890 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
500 mg | ¥ 8,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | Favipiravir (T-705) (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections. |
靶点活性 | RdRP:341 nM. |
体外活性 | Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2] |
体内活性 | In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3] |
细胞实验 | The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).(Only for Reference) |
别名 | T-705, 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide, 法匹拉韦, 法维拉韦 |
化合物与蛋白结合的复合物 |
Nsp7-Nsp8-Nsp12 SARS-CoV2 RNA-dependent RNA polymerase in complex with template:primer dsRNA and favipiravir-RTP |
分子量 | 157.1 |
分子式 | C5H4FN3O2 |
CAS No. | 259793-96-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 12 mg/mL(76.4 mM)
H2O: 5 mg/mL (31.82 mM)
DMSO: 29 mg/mL (184.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / H2O / DMSO | 1 mM | 6.3654 mL | 31.8269 mL | 63.6537 mL | 159.1343 mL |
5 mM | 1.2731 mL | 6.3654 mL | 12.7307 mL | 31.8269 mL | |
10 mM | 0.6365 mL | 3.1827 mL | 6.3654 mL | 15.9134 mL | |
20 mM | 0.3183 mL | 1.5913 mL | 3.1827 mL | 7.9567 mL | |
Ethanol / DMSO | 50 mM | 0.1273 mL | 0.6365 mL | 1.2731 mL | 3.1827 mL |
DMSO | 100 mM | 0.0637 mL | 0.3183 mL | 0.6365 mL | 1.5913 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Favipiravir 259793-96-9 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Others SARS-CoV DNA/RNA Synthesis Influenza Virus inhibit T705 SARS coronavirus T-705 Inhibitor T 705 6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide 法匹拉韦 法维拉韦 inhibitor